Page 51 - 87_01
P. 51
ANALES 37. Litman RS, Pagán OH, Cicero TJ. Abuse-deterrent opioid formula-
RANF tions. Anesthesiology. 2018 May;128(5):1015–26.
www.analesranf.com 38. Larance B, Dobbins T, Peacock A, Ali R, Bruno R, Lintzeris N, et al.
The effect of a potentially tamper-resistant oxycodone formulation
21. González-Escalada J. Actualizaciones en los aspectos socioeconó- on opioid use and harm: main findings of the National Opioid Me-
micos del dolor. In: Actualizaciones en el control del dolor: diez años dications Abuse Deterrence (NOMAD) study. The Lancet Psychiatry.
Reunión de expertos. Salamanca: Fundación Grünenthal; 2010. p. 2018 Feb 1;5(2):155–66.
145–69.
39. López S. Sistemas de liberación sostenida de administración oral y
22. Álvarez-Caramés MÁ, Navarro-Ribero M. Costes del tratamiento del parenteral. 2018.
dolor versus su no tratamiento. Aproximación a la realidad de Por-
tugal y España. Dor. 2016;24:1–9. 40. Alexander L, Mannion RO, Weingarten B, Fanelli RJ, Stiles GL. De-
velopment and impact of prescription opioid abuse deterrent for-
23. Damico V, Murano L, Cazzaniga F, Dal Molin A. Pain prevalence, mulation technologies. Drug Alcohol Depend. 2014 May
severity, assessment and management in hospitalized adult patients: 1;138(1):1–6.
a result of a multicenter cross sectional study. Ann Ist Super Sanita.
2018;54(3):194–200. 41. Smith K, Hopp M, Mundin G, Bond S, Bailey P, Woodward J, et al.
Low absolute bioavailability of oral naloxone in healthy subjects.
24. Mills SEE, Nicolson KP, Smith BH. Chronic pain: a review of its epi- Int J Clin Pharmacol Ther. 2012 May 1;50(05):360–7.
demiology and associated factors in population-based studies. Br J
Anaesth. 2019 Aug 1;123(2):e273–83. 42. Gudin JA. Assessment of Extended-Release Opioid Analgesics for the
Treatment of Chronic Pain. J Pain Palliat Care Pharmacother. 2013
25. Jones MR, Carney MJ, Kaye RJ, Prabhakar A, Kaye AD. Drug For- Feb;27(1):49–61.
mulation Advances in Extended-Release Medications for Pain Control.
Curr Pain Headache Rep. 2016 Jun 15;20(6):36. 43. Darwish M, Bond M, Tracewell W, Robertson P, Yang R. Pharmaco-
kinetics of hydrocodone extended-release tablets formulated with
26. Amabile CM, Bowman BJ. Overview of Oral Modified-Release Opioid different levels of coating to achieve abuse deterrence compared
Products for the Management of Chronic Pain. Ann Pharmacother. with a hydrocodone immediate- release/acetaminophen tablet in
2006 Jul 4;40(7–8):1327–35. healthy subjects. Clin Drug Investig. 2015 Jan 1;35(1):13–22.
27. Martín Montaner I. Formas farmacéuticas de liberacion modificada 44. Dhillon S. Hydrocodone Bitartrate ER (Hysingla® ER): A Review in
y estereoisómeros ¿Nos aportan algo en la práctica clínica? In: Bo- Chronic Pain. Clin Drug Investig. 2016 Nov 1;36(11):969–80.
letin de informacion Farmacoterapéutica de Navarra. 2005. p. 1–
10. 45. Gardner-Nix J, Mercadante S. The role of OROS® hydromorphone
in the management of cancer pain. Pain Pract. 2010 Jan
28. Argoff CE, Silvershein DI. A Comparison of Long-and Short-Acting 1;10(1):72–7.
Opioids for the Treatment of Chronic Noncancer Pain: Tailoring The-
rapy to Meet Patient Needs. Mayo Clin Proc. 2009;84(7):602–12. 46. Wallace MS, Thipphawong J. Clinical Trial Results with OROS®
Hydromorphone. J Pain Symptom Manage. 2007 Feb 1;33(2
29. Smith HS. Enteral controlled-release opioid delivery systems. Pain SUPPL.):S25–32.
Med. 2009;10.
47. Zingraff M, Reher M. Sustained release tablets with hydromorphone.
30. Varrassi G, Angeletti C, Guetti C, Marinangeli F, Paladini A. Systemic 2010.
opioid and chronic pain. Eur J Pain Suppl. 2009 Nov;3(2):77–83.
48. Ross EL, Hahn K. KADIAN® (morphine sulfate extended-release)
31. Martin C, De Baerdemaeker A, Poelaert J, Madder A, Hoogenboom Capsules for treatment of chronic, moderate-to-severe, nonmalignant
R, Ballet S. Controlled-release of opioids for improved pain mana- pain. Int J Clin Pract. 2008 Feb 1;62(3):471–9.
gement. Mater Today. 2016 Nov 1;19(9):491–502.
49. Krashin D, Murinova N, Trescot AM. Extended-release hydrocodone
32. Mugabure Bujedo B. Opioid formulations that prevent the recrea- - gift or curse? J Pain Res. 2013;6:53–7.
tional use: More questions than answers about their utility. Rev la
Soc Esp del Dolor. 2020;27(1):61–2. 50. Maincent J, Zhang F. Recent advances in abuse-deterrent technolo-
gies for the delivery of opioids. Int J Pharm. 2016 Aug
33. Cohen JP, Mendoza M, Roland C. Challenges Involved in the Deve- 20;510(1):57–72.
lopment and Delivery of Abuse-deterrent Formulations of Opioid
Analgesics. Clin Ther. 2018 Feb 1;40(2):334–44. 51. Lamb YN, Garnock-Jones KP, Keam SJ. Oxycodone DETERx® ER
Capsules: A Review in Severe, Chronic Pain. Drugs. 2016 Dec
34. Leslie S. The Contin delivery system: Dosing considerations. J Allergy 1;76(18):1759–69.
Clin Immunol. 1986;78(4 PART 2):768–73.
35. Miller DA, DiNunzio JC, Williams RO. Advanced formulation design:
Improving drug therapies for the management of severe and chronic
pain. Drug Dev Ind Pharm. 2008 Feb 11;34(2):117–33.
36. Reder RF. Opioid formulations: tailoring to the needs in chronic pain.
Eur J Pain. 2001 Dec;5(SA):109–11.
Sistemas de liberación prolongada de opioides: 49
analgesia y dependencia
Alexandre Pérez-López, Laura Gómez-Lázaro, et al.
An. Real Acad. Farm. Vol. 87. Nº1 (2021) · pp. 35 - 51
